Biotech Values

[exwannabe]

Re: Adam F and nimo

Adam is very negative on CTIC, and justifiably so, but his arguments seemed off to me.

He slammed the OS in the trial, but at n=84 in an indication that isn't quickly terminal you will not see much.

On cardio toxicity, the drug looks to be a vast improvement on the drug it is trying to replace.

And his comment "As to efficiacy, I won't even go there" was certainly snide.

OTOH, the point that even if approved CTCI is a horrid investment is certainly correct.